Drug Profile
Damoctocog alfa pegol - Bayer HealthCare Pharmaceuticals
Alternative Names: Antihemophilic factor [recombinant] PEGylated-aucl; BAY-949027; Damoctocog alfa pegol; Jivi; peg rFVIII; PEG rFVIII mutein; PEGylated B-Domain-Delted Recombinant rFVIII; PEGylated BDD-rFVIII; rFVIII glycopegylatedLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Class Amides; Amines; Antihaemorrhagics; Blood coagulation factors; Polyethylene glycols; Propionic acids; Pyrrolidines; Recombinant proteins
- Mechanism of Action Factor VIII replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Haemophilia A
- Registered Haemorrhage
Most Recent Events
- 27 Mar 2023 Registered for Haemophilia A (In adolescents, In children, In adults, Treatment-experienced) in Australia (IV)
- 23 Mar 2022 Bayer initiates a phase III trial for Haemophilia A (Treatment-experienced, In children) in Canada (IV,Infusion) (NCT05147662) (EudraCT2021-004858-30)
- 07 Dec 2021 Bayer HealthCare Pharmaceuticals plans a phase III trial for Haemophilia A (Treatment-experienced, In children) in Canada (IV,Infusion), (NCT05147662) (EudraCT2021-004858-30)